Pain point: You need to develop successful new drugs faster and at lower costs due to heightened competition and tighter budgets.
Solution from HLTH Europe: Hosting the Life Science Summit, featuring startup pitch sessions, access to our Health Transformation Summit (which serves as a nexus for those at the forefront of creating and influencing healthcare policy globally), and 1-1 curated networking opportunities through our Market Connect programme bringing you face-to-face with leading innovators, enabling you to discover cutting-edge R&D technologies and partnerships.

Why attend HLTH Europe?
Between now and 2033, the expiration of patents on dozens of brand-name medications is expected to create a revenue gap exceeding $200 billion. To bridge this loss, the pharmaceutical industry will increasingly rely on M&A activity, joint ventures, strategic alliances, R&D investment, and diversification. HLTH Europe will help you stay ahead of the curve.
HLTH Europe offers an unparalleled platform to meet and collaborate with leading:
Biotechs
Digital health, diagnostics and genomics innovators
Contract Research Organisations (CROs)
Investors
Senior policy-makers and regulators
Health systems
Government ministers

Seize the opportunity to unlock fresh partnerships, fuel your pipeline with transformative solutions, and adapt to evolving market demands. HLTH Europe is your gateway to strategic growth and innovation.
We solve your (business) problems:
Pressure on R&D for cost-effective innovation
Difficulty in identifying the right deals and partnerships
Pain point: We know companies like yours struggle with evaluating opportunities leading them to either committing to ineffective partnerships or missing high-value ones.
Solution from HLTH Europe: Discover innovative startups through our Market Connect Programme, designed to provide tailored 1:1 introductions and expert advisory services. We help pharma leaders identify and secure strategic partnerships with top-tier companies in the industry. By handpicking the most relevant opportunities, we make it effortless for you to connect with the right partners. You stay in control - choose who you want to meet, ensuring that every interaction is mutually beneficial and impactful.
Patent expiry
Pain point: The expiration of patents on dozens of brand-name medications is leaving a revenue gap you need to find a solution to.
Solution from HLTH Europe: To bridge this loss, the pharmaceutical industry will increasingly rely on M&A activity, joint ventures, strategic alliances, R&D investment, and diversification. At HLTH Europe you will be able to do all of this, and meet qualified, and vetted partners.
Uncertainty around digital health investments
Pain Point: Many pharma companies view digital health as a "luxury" rather than a necessity, with budgets fluctuating depending on management priorities. Some pharma companies are embracing this and investing heavily, while others cut back.
Solution from HLTH Europe: We connect you with seasoned experts to help you navigate the ever-evolving digital health landscape. Through startup pitches, interactive workshops, and compelling case studies, we showcase the proven ROI of digital health tools, equipping you with the insights and strategies needed to convince stakeholders of their strategic value.
Erosion of government and policy influence and challenges in price negotiation
Pain point: Pharma and life sciences companies face reduced access to key decision-makers in government and policymaking, limiting their ability to advocate for favourable regulations and pricing policies. Simultaneously, they are under pressure to secure the highest possible revenue during price negotiations with payers, while managing complex global market dynamics and regulatory expectations.
Solution from HLTH Europe: Our Health Transformation Summit, held in partnership with the World Economic Forum, unites ministers, senior policymakers, and regulators from around the world. HLTH Europe fosters meaningful connections with policy leaders, government representatives, and payers through exclusive networking dinners, workshops, roundtables, and tailored meetups. These high-impact engagements empower companies to rebuild influence, anticipate regulatory trends, and enhance their negotiating power - driving better pricing strategies and favorable policy outcomes.
2024 speaker highlights

David Evendon-Challis
Head of R&D and Chief Scientific Officer
Bayer Consumer Health
Switzerland

John Halamka
President, Mayo Clinic Platform
Mayo Clinic
USA

Karen DeSalvo
Chief Health Officer
USA

Karen Madden
Chief Technology Officer
Merck Life Science
USA

Simon Turner
Partner
Sofinnova Partners
France

Stephen Ranjan
Global Head, Digital Health Pharma Personalized Healthcare
Roche
Switzerland